Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1994 1
1997 1
1998 1
2002 1
2004 2
2005 1
2010 2
2011 4
2012 4
2013 3
2015 1
2016 3
2017 4
2018 4
2020 2
2021 2
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials.
Ostrowitzki S, Bittner T, Sink KM, Mackey H, Rabe C, Honig LS, Cassetta E, Woodward M, Boada M, van Dyck CH, Grimmer T, Selkoe DJ, Schneider A, Blondeau K, Hu N, Quartino A, Clayton D, Dolton M, Dang Y, Ostaszewski B, Sanabria-Bohórquez SM, Rabbia M, Toth B, Eichenlaub U, Smith J, Honigberg LA, Doody RS. Ostrowitzki S, et al. JAMA Neurol. 2022 Nov 1;79(11):1113-1121. doi: 10.1001/jamaneurol.2022.2909. JAMA Neurol. 2022. PMID: 36121669 Free PMC article. Clinical Trial.
A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease.
Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, Ashford E, Retout S, Hofmann C, Delmar P, Klein G, Andjelkovic M, Dubois B, Boada M, Blennow K, Santarelli L, Fontoura P; SCarlet RoAD Investigators. Ostrowitzki S, et al. Alzheimers Res Ther. 2017 Dec 8;9(1):95. doi: 10.1186/s13195-017-0318-y. Alzheimers Res Ther. 2017. PMID: 29221491 Free PMC article. Clinical Trial.
Tau: From research to clinical development.
Holtzman DM, Carrillo MC, Hendrix JA, Bain LJ, Catafau AM, Gault LM, Goedert M, Mandelkow E, Mandelkow EM, Miller DS, Ostrowitzki S, Polydoro M, Smith S, Wittmann M, Hutton M. Holtzman DM, et al. Among authors: ostrowitzki s. Alzheimers Dement. 2016 Oct;12(10):1033-1039. doi: 10.1016/j.jalz.2016.03.018. Epub 2016 May 4. Alzheimers Dement. 2016. PMID: 27154059 Review.
Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting.
Walsh RR, Krismer F, Galpern WR, Wenning GK, Low PA, Halliday G, Koroshetz WJ, Holton J, Quinn NP, Rascol O, Shaw LM, Eidelberg D, Bower P, Cummings JL, Abler V, Biedenharn J, Bitan G, Brooks DJ, Brundin P, Fernandez H, Fortier P, Freeman R, Gasser T, Hewitt A, Höglinger GU, Huentelman MJ, Jensen PH, Jeromin A, Kang UJ, Kaufmann H, Kellerman L, Khurana V, Klockgether T, Kim WS, Langer C, LeWitt P, Masliah E, Meissner W, Melki R, Ostrowitzki S, Piantadosi S, Poewe W, Robertson D, Roemer C, Schenk D, Schlossmacher M, Schmahmann JD, Seppi K, Shih L, Siderowf A, Stebbins GT, Stefanova N, Tsuji S, Sutton S, Zhang J. Walsh RR, et al. Among authors: ostrowitzki s. Neurology. 2018 Jan 9;90(2):74-82. doi: 10.1212/WNL.0000000000004798. Epub 2017 Dec 13. Neurology. 2018. PMID: 29237794 Free PMC article.
Arguments against precompetitive collaboration.
Vargas G, Boutouyrie B, Ostrowitzki S, Santarelli L. Vargas G, et al. Among authors: ostrowitzki s. Clin Pharmacol Ther. 2010 May;87(5):527-9. doi: 10.1038/clpt.2010.30. Clin Pharmacol Ther. 2010. PMID: 20407456 Review. No abstract available.
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Among authors: ostrowitzki s. Front Neurol. 2021 Oct 1;12:705407. doi: 10.3389/fneur.2021.705407. eCollection 2021. Front Neurol. 2021. PMID: 34659081 Free PMC article.
Assessing tumor angiogenesis using macromolecular MR imaging contrast media.
Brasch R, Pham C, Shames D, Roberts T, van Dijke K, van Bruggen N, Mann J, Ostrowitzki S, Melnyk O. Brasch R, et al. Among authors: ostrowitzki s. J Magn Reson Imaging. 1997 Jan-Feb;7(1):68-74. doi: 10.1002/jmri.1880070110. J Magn Reson Imaging. 1997. PMID: 9039595 Review.
Challenges, solutions, and recommendations for Alzheimer's disease combination therapy.
Hendrix JA, Bateman RJ, Brashear HR, Duggan C, Carrillo MC, Bain LJ, DeMattos R, Katz RG, Ostrowitzki S, Siemers E, Sperling R, Vitolo OV. Hendrix JA, et al. Among authors: ostrowitzki s. Alzheimers Dement. 2016 May;12(5):623-30. doi: 10.1016/j.jalz.2016.02.007. Epub 2016 Mar 24. Alzheimers Dement. 2016. PMID: 27017906
Safety, Tolerability, and Pharmacokinetics of High-Volume Subcutaneous Crenezumab, With and Without Recombinant Human Hyaluronidase in Healthy Volunteers.
Dolton MJ, Chesterman A, Moein A, Sink KM, Waitz A, Blondeau K, Kerchner GA, Hu N, Brooks L, Wetzel-Smith MK, Roden A, Deshmukh A, Peng K, Carrasco-Triguero M, Smith J, Ostrowitzki S, Quartino A. Dolton MJ, et al. Among authors: ostrowitzki s. Clin Pharmacol Ther. 2021 Nov;110(5):1337-1348. doi: 10.1002/cpt.2385. Epub 2021 Aug 27. Clin Pharmacol Ther. 2021. PMID: 34347883 Clinical Trial.
34 results